Arcus Biosciences (RCUS) Net Margin (2017 - 2026)
Arcus Biosciences (RCUS) posted quarterly Net Margin of 752.94% for Q1 2026, down 35294.0% year-over-year from N/an in Q1 2025, and down 134.41% quarter-over-quarter from 321.21% in Q4 2025.
Powered by 
Analysis
Arcus Biosciences (RCUS) Net Margin (2017 - 2026) Analysis & Trends
Arcus Biosciences' Net Margin history runs 10 years deep, the most recent figure standing at 752.94% for Q1 2026.
- In Q1 2026, Net Margin fell 35294.0% year-over-year to 752.94%; the TTM figure through Mar 2026 stood at 156.36% (up 12095.0% YoY), while the FY2025 annual figure was 142.91%, down 3323.0% from the prior year.
- Net Margin for Q1 2026 stood at 752.94%, down from 321.21% in the prior quarter.
- The five-year high for Net Margin was 2.76% in Q1 2024, with the low at 752.94% in Q1 2026.
- The 5-year median for Net Margin is 289.31% (2023), against an average of 324.18%.
- The sharpest annual moves came in 2022 and 2025: Net Margin surged 62720 bps in 2022, then slumped 39724 bps in 2025.
- Arcus Biosciences' Net Margin stood at 197.06% in 2022, then tumbled by 194 bps to 578.57% in 2023, then soared by 38 bps to 361.54% in 2024, then climbed by 11 bps to 321.21% in 2025, then plunged by 134 bps to 752.94% in 2026.
- Business Quant data shows RCUS's Net Margin at 752.94% in Q1 2026, 321.21% in Q4 2025, and 519.23% in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 32.99% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 30.23% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 31.16% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -539.31% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 13.90% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 12.74% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 12.09% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -3.12% |
| 10 | Arcus Biosciences | 3.74 Bn | 3.04 Bn | - | -221.95% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -221.95% |
| Mar 31, 2026 | -752.94% |
| Dec 31, 2025 | -321.21% |
| Sep 30, 2025 | -519.23% |
| Mar 31, 2025 | -400.00% |
| Dec 31, 2024 | -361.54% |
| Sep 30, 2024 | -191.67% |
| Jun 30, 2024 | -238.46% |
| Mar 31, 2024 | -2.76% |
| Dec 31, 2023 | -578.57% |
| Sep 30, 2023 | -221.88% |
| Jun 30, 2023 | -258.62% |
| Mar 31, 2023 | -320.00% |
| Dec 31, 2022 | -197.06% |
| Sep 30, 2022 | -196.97% |
| Jun 30, 2022 | -248.15% |
| Mar 31, 2022 | -377.78% |
| Dec 31, 2021 | 78.83% |
| Sep 30, 2021 | -824.17% |
| Jun 30, 2021 | -802.98% |